Open-label Randomized Controlled Trial of Controlled-release Formulation Budesonide in Indian Proteinuric IgA Nephropathy Patients

Introduction: IgA nephropathy (IgAN) in India is reported to have an onset at a younger age with faster progression to kidney failure requiring replacement therapy, where safe immunosuppression may improve the outcome. The gut-renal connection and multihit pathogenesis of IgAN targeted by an oral ta...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Pradeep Das, Arpita Ray Chaudhury, Saugat Dasgupta, Koushik Bhattacharya, Atanu Pal, Dipankar Sircar, Debabrata Sen
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-03-01
Schriftenreihe:	Kidney Medicine
Schlagworte:	IgA nephropathy targeted or controlled-release budesonide proteinuria eGFR treatment-emergent adverse events
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S259005952500202X
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!